Search results for "Liposarcoma"

showing 10 items of 25 documents

Differential diagnosis of myxoid soft tissue tumors. Experience in the Clinical University Hospital of Valencia.

2018

Abstract Soft tissue tumors with myxoid components are often a diagnostic challenge for the pathologist. We retrospectively reviewed 41 cases of soft tissue tumors with myxoid components diagnosed in our center over a five-year period. The most frequent diagnoses were myxofibrosarcoma and myxoid liposarcoma, followed by low-grade fibromyxoid sarcoma, low-grade fibromyxoid tumor and myxoid neurofibroma. Other diagnoses included were extraskeletal myxoid chondrosarcoma, myxoinflammatory fibroblastic sarcoma, low-grade myxoliposarcoma, myofibrosarcoma, fibromatosis, solitary fibrous tumor, non-ossifying variant of ossifying fibromyxoid tumor and ancient neurinoma with myxoid degeneration. Immu…

0301 basic medicineAdultSolitary fibrous tumorPathologymedicine.medical_specialtySoft Tissue NeoplasmsPathology and Forensic MedicineDiagnosis Differential03 medical and health sciences0302 clinical medicinemedicineHumansRetrospective StudiesMyxoid liposarcomabusiness.industryFibromatosisFibromyxoid TumorMyxofibrosarcomaSarcomaExtraskeletal Myxoid Chondrosarcomamedicine.diseaseHospitals030104 developmental biology030220 oncology & carcinogenesisSarcomaDifferential diagnosisbusinessRevista espanola de patologia : publicacion oficial de la Sociedad Espanola de Anatomia Patologica y de la Sociedad Espanola de Citologia
researchProduct

Primary Orbital Liposarcoma in Li-Fraumeni Cancer Family Syndrome: A Case Report

2005

Aims and background The aim of this study was to describe a case of primary orbital liposarcoma in Li-Fraumeni syndrome. Methods and study design In July 1998 a 20-year-old woman with a histological diagnosis of orbital myxoid liposarcoma underwent surgical treatment in our department. Since the patient's family pedigree met the clinical criteria for the diagnosis of LFS, molecular analysis was performed, which resulted in a molecular profile consistent with Li-Fraumeni syndrome. Results The patient underwent orbital exenteration extended to the upper eyelid; surgical reconstructive steps were performed to permit placement of an orbital prosthesis. Two years after primary surgery the patien…

AdultCancer Researchmedicine.medical_specialtymedicine.medical_treatmentBreast NeoplasmsLiposarcomaMalignancyliposarcoma Li-Fraumeni syndrome orbital surgery.030218 nuclear medicine & medical imagingLi-Fraumeni Syndrome03 medical and health sciences0302 clinical medicinemedicineHumansOrbital prosthesisFamily historyMyxoid liposarcomabusiness.industryLiposarcomaGeneral Medicinemedicine.diseaseSurgeryOncologyLi–Fraumeni syndrome030220 oncology & carcinogenesisOrbital NeoplasmsFemaleLymphadenectomybusinessQuadrantectomyTumori Journal
researchProduct

PML expression in soft tissue sarcoma: Prognostic and predictive value in alkylating agents/antracycline-based first line therapy

2012

Soft tissue sarcomas are aggressive tumors representing <1% of all adult neoplasms. Aim of our study was to evaluate promyelocytic leukemia gene expression value as prognostic factor and as a factor predicting response to alkylating agents/antracycline-based first line therapy. One hundred eleven patients affected by locally advanced and metastatic soft tissue sarcoma were selected. PML expression was evaluated by immunohistochemical analysis in pathological samples and in the corresponding normal tissue from each case. PML immunohistochemical results were correlated with prognosis and with radiological response to alkylating agents/antracycline-based first line therapy. PML expression was …

AdultMaleOncologymedicine.medical_specialtySettore MED/06 - Oncologia MedicaPhysiologyClinical BiochemistryCellDown-RegulationSoft Tissue NeoplasmsPromyelocytic Leukemia ProteinLiposarcomaPleomorphic LiposarcomaYoung AdultPredictive Value of TestsInternal medicinemedicineHumansAnthracyclinesAntineoplastic Agents AlkylatingPathologicalAgedRetrospective StudiesAged 80 and overPMLbusiness.industryTumor Suppressor ProteinsSoft tissue sarcomaNuclear ProteinsSoft tissueSarcomaCell BiologyMiddle AgedPrognosismedicine.diseaseImmunohistochemistrymedicine.anatomical_structuresoft tissue sarcomas; PMLDrug Resistance Neoplasmsoft tissue sarcomaImmunologyImmunohistochemistryFemaleSarcomabusinessTranscription Factors
researchProduct

Large left ventricular metastatis in patient with liposarcoma.

2014

Abstract Metastasis to the heart and pericardium are rare. We present a 44-year-old male with pleural dedifferentiated liposarcoma and multiple metastases, with no previous cardiological history and/or cardiac symptoms. A transthoracic echocardiogram during the advanced stage of disease showed a lobulated, large and mobile mass, with homogeneous echogenicity, attached to the basal posterior wall of the left ventricle via a broad base and with intracavitary growth. This mass extends to inferolateral and inferoseptal wall of the left ventricle.

AdultMalemedicine.medical_specialtyTime FactorsLarge left ventricular metastasiBiopsyHeart VentriclesPleural Neoplasms030204 cardiovascular system & hematologyDoppler echocardiographyLiposarcomaMetastasisHeart Neoplasms03 medical and health sciencesFatal Outcome0302 clinical medicineHumansMedicinePericardium030212 general & internal medicinePleural Neoplasmheart metastases liposarcomamedicine.diagnostic_testbusiness.industryEchogenicityGeneral Medicinemedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareEchocardiography DopplerTumor Burdenmedicine.anatomical_structureVentricleliposarcomaDisease Progressioncardiovascular systemRadiologyTransthoracic echocardiogramTomography X-Ray ComputedCardiology and Cardiovascular Medicinebusiness
researchProduct

Trabectedin-Related Liver Toxicity in Soft Tissue Sarcoma Patients: Always a Good Reason to Discontinue the Treatment?

2014

ABSTRACT Aim: A transient increase in liver enzymes is a well described side effect developed by almost 40% of soft tissue sarcoma (STS) patients treated with trabectedin, often leading to treatment delays or discontinuation. We retrospectively analysed the correlation between trabectedin-related liver toxicity and treatment outcome. Methods: Data from a total of 113 patients receiving trabectedin administered at the dose of 1.5 mg/m2 iv 24 hours in 3 reference centers were evaluated. This exploratory analysis was performed to assess the impact of liver toxicity (grade 3-4 AST and ALT increases) on the trabectedin efficacy and outcome in STS patients. All the patients included had metastati…

Cancer Researchmedicine.medical_specialtyLiver toxicityAnthracyclineSide effectPopulationLiposarcomaGastroenterologyInternal medicinemedicineeducationTrabectedineducation.field_of_studybusiness.industrySoft tissue sarcomaHazard ratioHematologymedicine.diseaseSynovial sarcomaDiscontinuationSurgeryOncologyPremedicationSarcomabusinessmedicine.drugAnnals of Oncology
researchProduct

CT and MR Imaging of Retroperitoneal Sarcomas: A Practical Guide for the Radiologist

2023

Primary retroperitoneal sarcomas (RPS) represent around 10–16% of all sarcomas, with liposarcomas and leiomyosarcomas being the most common subtypes. RPS have some peculiar characteristics, imaging appearances, worse prognosis, and complications compared to other locations of sarcoma. Commonly, RPS primarily present as large masses, progressively encasing adjacent structures, causing mass effect, and complications. RPS diagnosis is often challenging, and these tumors may be overlooked; however, failure to recognize RPS characteristics leads to a worse prognosis for the patients. Surgery is the only recognized curative treatment, but the anatomical constraints of the retroperitoneum limit th…

Cancer ResearchsarcomaOncologycomplicationsliposarcomaleiomyomamagnetic resonance imagingsolitary fibrous tumordifferential diagnosicomputed tomographynerve sheath tumorretroperitoneal neoplasmSettore MED/36 - Diagnostica Per Immagini E Radioterapia
researchProduct

Immunohistochemical detection of EWS and FLI-1 proteinss in Ewing sarcoma and primitive neuroectodermal tumors: comparative analysis with CD99 (MIC-2…

2001

The molecular analysis of the t(11;22) rearrangement involving EWS/FLI-1 genes is likely to be of diagnostic value in Ewing sarcoma (ES) and primitive neuroectodermal tumors (PNET). The objective of the current study was to analyze the immunohistochemical expression of the EWS and FLI-1 proteins in a group of small round-cell tumors (SRCT) to determine their specificity and relevance in their differential diagnosis. Forty-eight cases-10 conventional ES, 4 large-cell ES, 5 PNET, 9 neuroblastomas (NB), 6 undifferentiated synovial sarcomas (SS), 5 rhabdomyosarcomas (RB), 5 non-Hodgkin lymphomas (NHL), 1 round-cell liposarcoma, and 3 mesenchymal chondrosarcomas-were analyzed. Immunocytochemistr…

HistologyImmunocytochemistryCD99Sarcoma EwingLiposarcomaBiology12E7 AntigenSensitivity and SpecificityHeterogeneous-Nuclear RibonucleoproteinsPathology and Forensic Medicinechemistry.chemical_compoundAntigenAntigens CDProto-Oncogene ProteinsmedicineHumansNeuroectodermal Tumors PrimitiveProto-Oncogene Protein c-fli-1medicine.diseaseImmunohistochemistryDNA-Binding ProteinsMedical Laboratory TechnologyAntigen retrievalchemistryRibonucleoproteinsCancer researchTrans-ActivatorsImmunohistochemistrySarcomaDifferential diagnosisRNA-Binding Protein EWSCell Adhesion MoleculesApplied immunohistochemistrymolecular morphology : AIMM
researchProduct

RETROVESICAL MASS IN MEN

1999

We review the differential diagnosis and treatment of retrovesical masses in men.During the last 8 years 21 male patients 3 to 79 years old (mean age 47.1) presented with symptoms or signs of a retrovesical mass. Clinical features and diagnostic findings were reviewed, and related to surgical and histopathological findings.The retrovesical masses included prostatic utricle cyst in 3 cases, prostatic abscess in 1, seminal vesicle hydrops in 6, seminal vesicle cyst in 2, seminal vesicle empyema in 3, large ectopic ureterocele in 1, myxoid liposarcoma in 1, malignant fibrous histiocytoma in 1, fibrous fossa obturatoria cyst in 1, hemangiopericytoma in 1 and leiomyosarcoma in 1. In 17 patients …

LeiomyosarcomaAdultMalePathologymedicine.medical_specialtyAdolescentUrologyUrinary BladderDiagnosis DifferentialSeminal vesiclemedicineHumansCystChildAgedRetrospective StudiesHemangiopericytomaMyxoid liposarcomabusiness.industryDecision TreesMiddle Agedmedicine.diseaseProstatic utricleEmpyemamedicine.anatomical_structureChild PreschoolDifferential diagnosisGenital Diseases MalebusinessThe Journal of Urology
researchProduct

Safety and efficacy of intensity-modulated radiotherapy in the management of spermatic cord sarcoma.

2017

International audience; Purpose. - Spermatic cord sarcoma is a rare disease, which management remains controversial due to the lack of guidelines. The standard therapeutic approach is surgical: wide soft-tissue resection with radical inguinal orchidectomy, The diagnosis is made during the analysis of the specimen. The high rate of local recurrence indicates adjuvant radiotherapy of the tumor bed. The aim of this series is to determine the efficacy and safety of postoperative intensity-modulated radiotherapy for spermatic cord sarcomas. Patients and methods. - Our series included five consecutive cases of spermatic cord sarcoma treated between 2011 and 2014. The indications for radiotherapy …

LeiomyosarcomaMaleOrgans at Risk[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imagingmedicine.medical_treatment030232 urology & nephrologyParatesticular tumor[ SDV.CAN ] Life Sciences [q-bio]/Cancer[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicine0302 clinical medicineMedicineOrchiectomy[ SDV.IB ] Life Sciences [q-bio]/BioengineeringPatternsFederationRapidarc[ SDV.IB.IMA ] Life Sciences [q-bio]/Bioengineering/ImagingCancerAged 80 and overSpermatic CordSarcomaRadiotherapy DosageLiposarcomaMiddle AgedRetroperitoneal Sarcoma3. Good healthmedicine.anatomical_structureTreatment OutcomeOncology030220 oncology & carcinogenesisGenital Neoplasms MaleSoft-Tissue Sarcoma[SDV.IB]Life Sciences [q-bio]/BioengineeringSarcomaRadiodermatitisReoperationmedicine.medical_specialtyPrognostic-Factors[SDV.CAN]Life Sciences [q-bio]/Cancer[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineSpermatic cord03 medical and health sciencesTherapeutic approachHumansRadiology Nuclear Medicine and imagingIMRTAgedRetrospective StudiesRadiotherapybusiness.industryCancermedicine.diseaseRadiation-TherapySurgeryRadiation therapyRadiotherapy Intensity-ModulatedNeoplasm Recurrence LocalbusinessLigationOrchiectomyRare diseaseFollow-Up StudiesCancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
researchProduct

PML down-regulation in soft tissue sarcomas

2010

To date, little is known concerning the promyelocytic leukemia gene (PML) status in tumors of different origin, and its expression has never been evaluated in soft tissue sarcoma. The aim of the present study is focused on the identification of differences in terms of PML protein expression between different types of soft tissue sarcoma and the corresponding normal surrounding tissue. PML protein expression has been assessed by immunohistochemistry in six different histologic types of soft tissue sarcoma (synovial sarcoma, myofibroblastic sarcoma, angiosarcoma, liposarcoma, pleomorphic sarcoma, and leiomyosarcoma) and in the corresponding normal surrounding tissue. PML resulted significantl…

LeiomyosarcomaPathologymedicine.medical_specialtyPhysiologysoft tissue tumorSettore MED/06 - Oncologia MedicaClinical BiochemistryDown-RegulationLiposarcomaPromyelocytic Leukemia ProteinPleomorphic LiposarcomaPML sarcomasPromyelocytic leukemia proteinmedicineHumanssarcomasneoplasmsMyxoid liposarcomaPMLbiologybusiness.industrySoft tissue sarcomaTumor Suppressor ProteinsNuclear ProteinsSarcomaCell BiologyAnatomymedicine.diseaseImmunohistochemistrySynovial sarcomabody regionsbiology.proteinSarcomabusinessTranscription Factors
researchProduct